Outlook Therapeutics wins FDA approval for LYTENAVA in wet AMD

Reuters2026/09/10 13:10

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Outlook Therapeutics secured FDA approval for LYTENAVA, an ophthalmic bevacizumab formulation to treat wet age-related macular degeneration.
U.S. launch planned before end-2026, targeting conversion of off-label bevacizumab use in the retina market.
Company flagged a path to more than $500 million in annual U.S. sales by 2030.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Outlook Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609100910PRIMZONEFULLFEED9824119) on September 10, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Outlook Therapeutics wins FDA approval for LYTENAVA in wet AMD

You may also like

Crypto prices